Suppr超能文献

血小板反应蛋白的1型和2型重复序列的肝素结合结构域介导其与人乳腺癌细胞的相互作用。

Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells.

作者信息

Incardona F, Lawler J, Cataldo D, Panet A, Legrand Y, Foidart J M, Legrand C

机构信息

U 353 INSERM, Protéases et Protéines Adhésives des Cellules Vasculaires et Sanguines, Hôpital Saint Louis, Paris, France.

出版信息

J Cell Biochem. 1996 Sep 15;62(4):431-42. doi: 10.1002/(sici)1097-4644(19960915)62:4<431::aid-jcb1>3.0.co;2-n.

Abstract

Thrombospondin is an adhesive glycoprotein that promotes breast cancer cell adhesion to human vascular endothelial cells (Incardona et al., 1995). In this study, we have identified the molecular domains of thrombospondin that mediate its binding to specific receptors on the human breast adenocarcinoma cell line, MDA-MB-231. Two recombinant fragments from the amino-terminus (TSPN18 and TSPN28), and the fusion proteins of the type 1 and type 2 repeats of human thrombospondin, inhibited binding of radiolabeled thrombospondin to MDA-MB-231 cells in suspension by 40-60% at 50 micrograms/ml whereas the type 3 repeat, carboxy-terminus and unfused glutathione-S-transferase as well as the synthetic peptide Gly-Arg-Gly-Asp-Ser (500 micrograms/ml) had little or no effect. Heparin and various glycosaminoglycans as heparan sulfate, chondroitin sulfates A, B or C, and fucoidan inhibited thrombospondin binding to MDA-MB-231 cells by more than 60% whereas dextran sulfate had only little effect. Treatment of cells with heparitinase, chondroitinase ABC, and hyaluronidase, but not with neuraminidase, induced 30-50% inhibition of thrombospondin binding suggesting the participation of both heparan sulfate and chondroitin sulfate cell surface-associated molecules. Inhibition of proteoglycan sulfation by chlorate or inhibition of glycosaminoglycan chain formation by two beta-D-xylosides also led to a substantial inhibition of thrombospondin binding. Our results indicate that several domains within the thrombospondin molecule, namely the amino-terminus, type 1 and type 2 repeats, participate in its binding to specific receptors bearing sulfated glycosaminoglycans on MDA-MB-231 cells. Biological assays have indicated that, in addition to these domains, the peptide Gly-Arg-Gly-Asp-Ser inhibited MDA-MB-231 cell attachment to thrombospondin suggesting that the last type 3 repeat of the molecule may also contribute to its cell adhesive activity.

摘要

血小板反应蛋白是一种黏附性糖蛋白,可促进乳腺癌细胞与人血管内皮细胞的黏附(因卡多纳等人,1995年)。在本研究中,我们已鉴定出血小板反应蛋白的分子结构域,这些结构域介导其与人类乳腺腺癌细胞系MDA-MB-231上的特定受体结合。来自氨基末端的两个重组片段(TSPN18和TSPN28)以及人血小板反应蛋白1型和2型重复序列的融合蛋白,在50微克/毫升时可使放射性标记的血小板反应蛋白与悬浮的MDA-MB-231细胞的结合抑制40%-60%,而3型重复序列、羧基末端和未融合的谷胱甘肽-S-转移酶以及合成肽甘氨酸-精氨酸-甘氨酸-天冬氨酸-丝氨酸(500微克/毫升)几乎没有影响。肝素和各种糖胺聚糖,如硫酸乙酰肝素、硫酸软骨素A、B或C以及岩藻依聚糖,可使血小板反应蛋白与MDA-MB-231细胞的结合抑制超过60%,而硫酸葡聚糖的影响很小。用乙酰肝素酶(heparitinase)、软骨素酶ABC和透明质酸酶处理细胞,但不用神经氨酸酶处理,可使血小板反应蛋白结合抑制30%-50%,这表明硫酸乙酰肝素和硫酸软骨素细胞表面相关分子均参与其中。用氯酸盐抑制蛋白聚糖硫酸化或用两种β-D-木糖苷抑制糖胺聚糖链形成也会导致血小板反应蛋白结合的显著抑制。我们的结果表明,血小板反应蛋白分子内的几个结构域,即氨基末端、1型和2型重复序列,参与其与MDA-MB-231细胞上带有硫酸化糖胺聚糖的特定受体的结合。生物学试验表明除了这些结构域之外,肽甘氨酸-精氨酸-甘氨酸-天冬氨酸-丝氨酸可抑制MDA-MB-231细胞与血小板反应蛋白的黏附,这表明该分子的最后一个3型重复序列也可能有助于其细胞黏附活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验